- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07284420
ADAPT Forward 1 - ISA1 - en studie for å evaluere Empasiprubart IV som tilleggsbehandling til Efgartigimod IV hos deltakere med AChR-Ab-seropositiv generalisert myasthenia gravis med en partiell klinisk respons til Efgartigimod
En ISA til Master Protocol ARGX-999-2-MG-2000 for en utforskende, fase 2a, proof-of-concept-studie for å evaluere sikkerheten, toleransen og effekten av Empasiprubart IV som tilleggsterapi til Efgartigimod IV hos deltakere med AChR-Ab-seropositiv generalisert myasthenia gravis med en delvis klinisk respons til Efgartigimod
This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.
The aim of this ISA1 is to evaluate the safety and therapeutic relevance of empasiprubart as add-on therapy to efgartigimod in participants with AChR-Ab seropositive generalized myasthenia gravis.
The ADAPT Forward master protocol is registered on https://clinicaltrials.gov/study/NCT07294170
More information can be found here: https://clinicaltrials.argenx.com/adaptforward1
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Once the master protocol and ISA1 screening periods are completed, eligible participants can enroll in the run-in period (part A) where they will receive efgartigimod IV. Eligible participants can then continue to the add-on period (part B) where they will receive both efgartigimod IV and empasiprubart IV.
Participants who are not eligible for part B will continue directly to the safety follow-up period (part C) where they will receive efgartigimod IV only.
The study duration for each participant is approximately up to 54 weeks.
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Sabine Coppieters, MD
- Telefonnummer: 857-350-4834
- E-post: clinicaltrials@argenx.com
Studiesteder
-
-
-
Leuven, Belgia, 3000
- Rekruttering
- UZ Leuven - PPDS
-
Ta kontakt med:
- Kristl Claeys, MD
- Telefonnummer: +3216344278
- E-post: kristl.claeys@uzleuven.be
-
-
-
-
California
-
Carlsbad, California, Forente stater, 92011
- Rekruttering
- Profound Research LLC - Carlsbad
-
Ta kontakt med:
- Gregory Sahagian, MD
- Telefonnummer: 760-732-0557
- E-post: greg@profoundresearch.com
-
-
Florida
-
Miami, Florida, Forente stater, 33176
- Rekruttering
- Visionary Investigators Network
-
Ta kontakt med:
- Andrew Lerman, MD
- Telefonnummer: 786-655-8010
- E-post: alerman@fcneurology.net
-
Tampa, Florida, Forente stater, 33620
- Rekruttering
- University of South Florida
-
Ta kontakt med:
- Tuan Vu, MD
- Telefonnummer: 813-974-9413
- E-post: tvu6@usf.edu
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114-2621
- Rekruttering
- Massachusetts General Hospital
-
Ta kontakt med:
- Amanda Guidon, MD
- Telefonnummer: 617-726-3642
- E-post: aguidon@mgb.org
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48202-2608
- Rekruttering
- Henry Ford Health Systems
-
Ta kontakt med:
- Kavita Grover, MD
- Telefonnummer: 313-916-1906
- E-post: kgrover1@hfhs.org
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89106
- Rekruttering
- Profound Research LLC at Las Vegas Neurology Center
-
Ta kontakt med:
- Paul Janda, MD
- Telefonnummer: +1 857-350-4834
- E-post: Paul.Janda@profoundresearch.com
-
-
New York
-
Amherst, New York, Forente stater, 14226
- Rekruttering
- Dent Neurologic Institute - Amherst
-
Ta kontakt med:
- Luisa Rojas Estupinan, MD
- Telefonnummer: 716-250-2000
- E-post: aemborsky@dentinstitute.com
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27514-4221
- Rekruttering
- University of North Caroline at Chapel Hill-170 Manning Dr
-
Ta kontakt med:
- James Howard, MD
- Telefonnummer: +1 857-350-4834
- E-post: howardj@neurology.unc.edu
-
Durham, North Carolina, Forente stater, 27710-0001
- Rekruttering
- Duke Early Phase Clinical Research Unit - PPDS
-
Ta kontakt med:
- Vern Juel, MD
- Telefonnummer: 919-668-6326
- E-post: vern.juel@duke.edu
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45219=2364
- Rekruttering
- University of Cincinnati Medical Center - Goodman St
-
Ta kontakt med:
- Hani Kushlaf
- Telefonnummer: (513) 558-0269
- E-post: kushlaha@ucmail.uc.edu
-
Columbus, Ohio, Forente stater, 43221-3502
- Rekruttering
- Ohio State Martha Morehouse Outpatient Care
-
Ta kontakt med:
- Miriam Freimer, MD
- Telefonnummer: 614-293-4969
- E-post: Miriam.Freimer@osumc.edu
-
-
Tennessee
-
Chattanooga, Tennessee, Forente stater, 37403
- Rekruttering
- Erlanger Health System
-
Ta kontakt med:
- Joshua Alpers, MD
- Telefonnummer: 423-778-3900
- E-post: joshua.alpers@erlanger.org
-
-
Texas
-
Austin, Texas, Forente stater, 78756
- Rekruttering
- National Neuromuscular Research Institute
-
Ta kontakt med:
- Yessar Hussain, MD
- Telefonnummer: 512-920-0140
- E-post: marisol@austinneuromuscle.com
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- University of Texas- San Antonio - Health Science Center - PPDS
-
Ta kontakt med:
- Ratna Bhavaraju-Sanka, MD
- Telefonnummer: 210-567-8229
- E-post: BhavarajuSan@uthscsa.edu
-
-
-
-
-
Athens, Hellas, 115 28
- Rekruttering
- Eginitio Hospital
-
Ta kontakt med:
- Vasiliki Zouvelou, MD
- Telefonnummer: +306978000000
- E-post: vzouvelu@med.uoa.gr
-
Thessaloniki, Hellas, 546 36
- Rekruttering
- AHEPA University General Hospital of Thessaloniki
-
Ta kontakt med:
- Marianthi Arnaoutoglou, MD
- Telefonnummer: +30 6937099722
- E-post: marnaoutoglou@yahoo.com
-
-
-
-
-
Milan, Italia, 20133
- Rekruttering
- Fondazione IRCCS Istituto Neurologico Carlo Besta
-
Ta kontakt med:
- Carlo Antozzi, MD
- Telefonnummer: 857-350-4834
- E-post: clinicaltrials@argenx.com
-
Naples, Italia, 80131
- Rekruttering
- AORN Antonio Cardarelli
-
Ta kontakt med:
- Francesco Habetswallner, MD
- E-post: francesco.habetswallner@aocardarelli.it
-
-
Lombardy
-
Bergamo, Lombardy, Italia, 24127
- Rekruttering
- ASST Papa Giovanni XXIII - Ospedale Papa Giovanni XXIII
-
Ta kontakt med:
- Giorgia Camera, MD
- Telefonnummer: 857-350-4834
- E-post: clinicaltrials@argenx.com
-
-
-
-
-
Hanamaki, Japan, 025-0075
- Rekruttering
- General Hanamaki Hospital - Kajomachi
-
Ta kontakt med:
- Kimiaki Utsugisawa, MD
- E-post: kutsugisawa@gmail.com
-
Narita, Japan, 286-8520
- Rekruttering
- IUHW Narita Hospital
-
Ta kontakt med:
- Hiroyuki Murai, MD
- E-post: murai@iuhw.ac.jp
-
-
Ibaraki
-
Tsukuba, Ibaraki, Japan, 305-8576
- Rekruttering
- University of Tsukuba Hospital
-
Ta kontakt med:
- Shinji Saiki, MD
- Telefonnummer: +1 857-350-4834
- E-post: clinicaltrials@argenx.com
-
-
Kanagawa
-
Kawasaki-shi, Kanagawa, Japan, 216-8511
- Rekruttering
- St. Marianna University Hospital
-
Ta kontakt med:
- Kenzo Sakurai, MD
- Telefonnummer: +1 857-350-4834
- E-post: clinicaltrials@argenx.com
-
-
Miyagi
-
Sendai, Miyagi, Japan, 983-0045
- Rekruttering
- National Hospital Organization Sendai Medical Center
-
Ta kontakt med:
- Yasushi Suzuki, MD
- Telefonnummer: +1 857-350-4834
- E-post: clinicaltrials@argenx.com
-
-
-
-
-
Warsaw, Polen, 00-665
- Rekruttering
- Warszawski Uniwersytet Medyczny
-
Ta kontakt med:
- Anna Kostera-Pruszczyk, MD
- Telefonnummer: +48 22 599 2858
- E-post: anna.kostera-pruszczyk@wum.edu.pl
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen
- Rekruttering
- MICS Centrum Medyczne Bydgoszcz
-
Ta kontakt med:
- Lukasz Rzepiński, MD
- Telefonnummer: +48523401414
- E-post: lukasz.rzepinski@mics.medicover.com
-
-
Silesian Voivodeship
-
Katowice, Silesian Voivodeship, Polen, 40-689
- Rekruttering
- Centrum Medyczne Neurologia Slaska
-
Ta kontakt med:
- Marek Smilowski, MD
- Telefonnummer: +48500282494
- E-post: marek.smilowski@neurologiaslaska.pl
-
-
-
-
-
Barcelona, Spania, 08041
- Rekruttering
- Hospital de La Santa Creu i Sant Pau
-
Ta kontakt med:
- Elena Cortes Vicente, MD
- E-post: ecortes@santpau.cat
-
-
Malaga
-
Málaga, Malaga, Spania, 29010
- Rekruttering
- Hospital Regional Universitario de Malaga - Hospital General
-
Ta kontakt med:
- Guillermina Garcia Martin, MD
- Telefonnummer: +34951291135
- E-post: guille.garcia.eecc@gmail.com
-
-
-
-
-
Berlin, Tyskland, 10117
- Rekruttering
- Charité - Universitätsmedizin Berlin
-
Ta kontakt med:
- Sarah Hoffmann, MD
- Telefonnummer: +49 30 450 539734
- E-post: sarah.hoffmann@charite.de
-
Göttingen, Tyskland, 37075
- Rekruttering
- Universitätsmedizin Göttingen
-
Ta kontakt med:
- Jana Zschuentzsch, MD
- Telefonnummer: +49551399889
- E-post: j.zschuentzsch@med.uni-goettingen.de
-
Würzburg, Tyskland, 97080
- Rekruttering
- Universitätsklinikum Würzburg
-
Ta kontakt med:
- Axel Haarmann, MD
- Telefonnummer: +4993120123595
- E-post: haarmann_a@ukw.de
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Is seropositive for anti-acetylcholine receptor antibodies (AChR-Ab)
- Has confirmed diagnosis of gMG and is Myasthenia Gravis Foundation of America (MGFA) Class II, III, IVa, or IVb
- Has documented immunization against encapsulated bacterial pathogens (Neisseria meningitidis and Streptococcus pneumoniae) within 5 years of ISA screening or is willing to receive immunization at least 14 days before the first study drug administration
Exclusion Criteria:
- Clinical diagnosis of systemic lupus erythematosus (SLE)
- Any known complement deficiency
- Current administration of a complement inhibitor or received zilucoplan or eculizumab <2 months or ravulizumab <6 months before the first study drug administration
- Patients proven to be refractory to efgartigimod (ie, not achieving a clinically meaningful improvement in total Myasthenia Gravis Activities of Daily Living (MG-ADL) score defined as an improvement of ≥2 points)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Efgartigimod IV + Empasiprubart IV
Participants receive efgartigimod IV in part A, B and C and empasiprubart IV in part B |
Intravenous infusion of empasiprubart Intravenous infusion of efgartigimod |
|
Eksperimentell: Efgartigimod IV (part A + C)
Participants not eligible for part B, receiving efgartigimod IV in part A and C |
Intravenous infusion of efgartigimod |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Forekomst av bivirkninger og alvorlige bivirkninger i del A og B
Tidsramme: Opptil 21 uker
|
Opptil 21 uker
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
MG-ADL total score change from baseline at week 18 in part B (cycle 2 day 29) compared with MG ADL total score change from baseline at week 4 in part A
Tidsramme: Up to 18 weeks
|
The Myasthenia Gravis Activities of Daily Living (MG- ADL) scale is an 8-item instrument used to assess MG symptoms and their effects on daily activities. The total score ranges from 0 (normal symptoms) to 24 (most severe symptoms) |
Up to 18 weeks
|
|
Proportion of participants reaching MSE at any point in part B cycles 1 and 2, and part B cycles 1 or 2
Tidsramme: Up to 21 weeks
|
MSE: Minimal symptom expression |
Up to 21 weeks
|
|
MG-ADL total score changes from baseline over time in part B compared with part A
Tidsramme: Up to 21 weeks
|
The Myasthenia Gravis Activities of Daily Living (MG- ADL) scale is an 8-item instrument used to assess MG symptoms and their effects on daily activities. The total score ranges from 0 (normal symptoms) to 24 (most severe symptoms) |
Up to 21 weeks
|
|
QMG total score change from baseline at week 18 in part B (cycle 2 day 29) compared with QMG total score change from baseline at week 4 in part A
Tidsramme: Up to 18 weeks
|
The Quantitative myasthenia gravis (QMG) includes 13 items that measure endurance or fatigability and accounts for fluctuations in disease state. The total score ranges from 0 (no disease severity) to 39 (highest disease severity) |
Up to 18 weeks
|
|
QMG total score changes from baseline over time in part B compared with part A
Tidsramme: Up to 21 weeks
|
The Quantitative myasthenia gravis (QMG) includes 13 items that measure endurance or fatigability and accounts for fluctuations in disease state. The total score ranges from 0 (no disease severity) to 39 (highest disease severity) |
Up to 21 weeks
|
|
Proportion of participants who have a 50% MG ADL total score improvement in part B cycles 1 and 2
Tidsramme: Up to 21 weeks
|
The Myasthenia Gravis Activities of Daily Living (MG ADL) scale is an 8-item instrument used to assess MG symptoms and their effects on daily activities. The total score ranges from 0 (normal symptoms) to 24 (most severe symptoms) |
Up to 21 weeks
|
|
Proportion of participants who have positive PASS in part B cycles 1 and 2, and part B cycles 1 or 2
Tidsramme: Up to 21 weeks
|
PASS: Patient acceptable symptom state |
Up to 21 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i nervesystemet
- Neoplasmer etter nettsted
- Neoplasmer
- Nevromuskulære sykdommer
- Autoimmune sykdommer
- Sykdommer i immunsystemet
- Autoimmune sykdommer i nervesystemet
- Nevrodegenerative sykdommer
- Paraneoplastiske syndromer, nervesystemet
- Neoplasmer i nervesystemet
- Paraneoplastiske syndromer
- Nevromuskulære Junction-sykdommer
- Myasthenia Gravis
Andre studie-ID-numre
- ARGX-999-2-MG-20001
- 2025-522492-28-00 (Ctis)
- 2025 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .